[{"id":"4d7b9d47-ea39-4190-9ede-c3f2ba2819fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05541822","created_at":"2022-09-15T14:59:05.101Z","updated_at":"2024-07-02T16:35:02.112Z","phase":"Phase 2","brief_title":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation","source_id_and_acronym":"NCT05541822","lead_sponsor":"Abion Inc","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vabametkib (ABN401)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/17/2023","start_date":" 01/17/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-05-22"},{"id":"d50a34e4-2472-47b7-9a2f-79140a198661","acronym":"","url":"https://clinicaltrials.gov/study/NCT04052971","created_at":"2022-05-05T23:54:22.816Z","updated_at":"2024-07-02T16:35:18.863Z","phase":"Phase 1","brief_title":"To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation","source_id_and_acronym":"NCT04052971","lead_sponsor":"Abion Inc","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vabametkib (ABN401)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-19"},{"id":"207a0fa4-5244-4f22-8a4a-44b8db2c85e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05882292","created_at":"2023-05-31T15:05:49.662Z","updated_at":"2024-07-02T16:35:46.918Z","phase":"Phase 2","brief_title":"A Phase II Study of ABN401 in Advanced Solid Tumors With c-MET Gene Aberration","source_id_and_acronym":"NCT05882292","lead_sponsor":"Yonsei University","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vabametkib (ABN401)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-05-31"}]